{"schema_version":"secwatch.filing_event.v1","accession":"0001638833-23-000019","form_type":"8-K","ticker":"SGRY","cik":"0001638833","company_name":"Surgery Partners, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.955819+00:00","generated_at":"2026-06-18T18:05:19.771713+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Surgery Partners Q4 revenue up 15.9% to $707.1M; sets 2023 EBITDA guidance >$425M","bullets":["Revenue $707.1M in Q4 (+15.9% YoY); full-year revenue $2.5B (+14.1%).","Net loss attributable to common $23.4M in Q4; full-year net loss $54.6M.","Adjusted EBITDA $120.8M in Q4 (+5.6% YoY); full-year $380.2M (+12.0%).","Days adjusted same-facility revenue +10.7% in Q4; +7.7% for full year.","2023 guidance: revenue >$2.75B, Adjusted EBITDA >$425M; liquidity >$830M."],"urls":{"canonical":"https://secwatch.observer/filing/0001638833-23-000019","json":"https://secwatch.observer/filing/0001638833-23-000019.json","markdown":"https://secwatch.observer/filing/0001638833-23-000019.md","text":"https://secwatch.observer/filing/0001638833-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000019/0001638833-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000019/sgry-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:05:19.771713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fd66518a8b7f8fa497b0794796164086fd5e218","claim":"Surgery Partners, Inc. reported full year 2023 results: revenue greater than $2.75 billion. Guidance raised.","evidence_excerpt":"The Company projects 2023 revenues to be greater than $2.75 billion, and projects 2023 Adjusted EBITDA to be greater than $425 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000019/0001638833-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"greater than $2.75 billion"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"73cb5d263f3426938270026f01f27faccb7d3081","claim":"Surgery Partners, Inc. reported financial results for fourth quarter ended December 31, 2022.","evidence_excerpt":"Revenue for the fourth quarter of 2022 increased 15.9% to $707.1 million from $610.2 million for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000019/0001638833-23-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"73cb5d263f3426938270026f01f27faccb7d3081","claim":"Surgery Partners, Inc. reported financial results for fourth quarter ended December 31, 2022.","evidence_excerpt":"For the fourth quarter of 2022, the Company’s 1 net loss attributable to common stockholders and Adjusted EBITDA were $23.4 million and $120.8 million, respectively, compared to $0.1 million and $114.4 million for the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000019/0001638833-23-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f85ac30263d4be913c8f15fc20b83fcf0698ad96","claim":"Surgery Partners, Inc. reported financial results for full year ended December 31, 2022.","evidence_excerpt":"Revenue for 2022 increased 14.1% to $2,539.3 million from $2,225.1 million in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000019/0001638833-23-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f85ac30263d4be913c8f15fc20b83fcf0698ad96","claim":"Surgery Partners, Inc. reported financial results for full year ended December 31, 2022.","evidence_excerpt":"For the full year 2022, the Company’s net loss attributable to common stockholders and Adjusted EBITDA was $54.6 million and $380.2 million, respectively, compared to $81.2 million and $339.6 million in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000019/0001638833-23-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}